Follow our progress.

Milestones in our journey to reinvent genetic testing.

View full list

Press Releases

Sarepta and Invitae Expand Partnership to Advance Clinical Research in Duchenne Muscular Dystrophy

Sarepta and Invitae Expand Partnership to Advance Clinical Research in Duchenne Muscular Dystrophy

May 07, 2018

The program helps clinicians identify patients who may be eligible for Sarepta’s clinical trials

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced the expansion of its partnership with Sarepta Therapeutics, Inc. (NASDAQ: SRPT) to assist clinicians in identifying patients with Duchenne muscular dystrophy (DMD).

“Our partnership with is important to advancing our clinical study objectives across our entire RNA-based platform,” said Doug Ingram, Sarepta’s President and CEO. “Sarepta’s goal is to treat 100% of eligible individuals with DMD and using the best tools to enable earlier genetic-based identification of patients is a necessary element to eventually achieving that aspiration.”

DMD is a rare, fatal neuromuscular genetic disease that occurs in approximately one in every 3,500 – 5,000 males worldwide and is caused by a change or mutation in the gene that encodes instructions for dystrophin. Genetic testing is required to confirm the diagnosis and identify the disease-causing mutation in the dystrophin gene.

The program is part of Invitae’s network of partnerships that connect patients and clinicians to treatment and research.

“Genetic information is a powerful tool that can improve healthcare for patients and their families, both by helping make quicker diagnoses of rare diseases and also by providing access to treatment options and research opportunities that rely on patients and their providers having their genetic information,” said Robert Nussbaum, MD, chief medical officer, Invitae. “Our network is designed to make it easier for patients and researchers to connect with each other. Partnerships like ours with Sarepta demonstrate how genetics can be used to advance research in the areas of medicine that need it most.”

For more information on Sarepta’s clinical trials, visit

About Sarepta
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying DMD drug candidates. For more information, please visit

About Invitae
Invitae Corporation (NYSE: NVTA) is a genetics company whose mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae’s goal is to aggregate most of the world’s genetic tests into a single service with higher quality, faster turnaround time and lower prices.

Invitae’s Safe Harbor Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the importance of the company’s partnership with Sarepta to advance Sarepta’s clinical study objectives; Sarepta’s goal to treat 100% of eligible individuals with DMD; that genetic information is a powerful tool that can improve healthcare for patients and their families; the benefits of the company’s network; and that the company’s partnership with Sarepta demonstrates how genetics can be used to advance research. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the company’s ability to use rapidly changing genetic data to interpret test results accurately and consistently; laws and regulations applicable to the company’s business; the company’s history of losses; the company’s ability to compete; and the other risks set forth in the company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Annual Report on Form 10-K for the year ended December 31, 2017. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.

Source: Invitae Corporation

Laura D’Angelo


Return to press releases